分心氣飮의 도파민 세포 보호 효과
Neuroprotective Effects of Bunsimgieum
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: The depression accompanied with menopuase shows the relation with the dopamine secretion. These studies were undertaken to evaluate the anti- oxidative and neuroprotective effects of Bunsimgieum(BSGE) on dopaminergic neurons. Methods: To estimate the antioxidant effects, we carried out 1.1-diphenyl-2- picrylhydrazyl (DPPH) free radical scavenging assay, 2,2'-azinobis-(3-ethylbenzothiazoline -6-sulfonic acid (ABTS) radical cation decolorization assay, and measurement of total polyphenolic content. To evaluate neuroprotective effect of BSGE in vitro, We performed thiazolyl blue tetrazolium bromide (MTT) assay, reactive oxygen species (ROS) creation in SH-SY5Y. Tyrosine hydroxylase (TH) immunocytochemistry, nitric oxide (NO) assay, and TNF-α assay in primary rat mesencephalic dopaminergic neurons. Results: The DPPH free radical and the ABTS radical cation inhibition activities were increased at a dose dependent manner. Total polyphenolic content was 0.83%. In SH-SY5Y culture, BSGE significantly increased the decreased cell viability by 6-OHDA at the concentrations of 10㎍/㎖ in pre-treatment group, 0.1-200㎍/㎖ in post-treatment group. The production of ROS induced by 6-OHDA was significantly inhibited in BSGE treated group. In mesencephalic dopaminergic cell culture, the BSGE group reduced the dopaminergic cell loss against 6-OHDA toxicity and the production of No and TNF-α at the concentration of 5㎍/㎖. Conclusion: These results shows that BSGE has antioxidant and neuroprotective effects in the dopaminergic cells through decreasing the production of ROS, NO and TNF-α which can cause many neurodegenerative changes in brain cell. We suggest that BSGE could be useful for the treatment of postmenopausal depression related with the decrease of dopamine.
Abstract
Purpose: The depression accompanied with menopuase shows the relation with the dopamine secretion. These studies were undertaken to evaluate the anti- oxidative and neuroprotective effects of Bunsimgieum(BSGE) on dopaminergic neurons. Methods: To estimate the antioxidant effects, we carried out 1.1-diphenyl-2- picrylhydrazyl (DPPH) free radical scavenging assay, 2,2'-azinobis-(3-ethylbenzothiazoline -6-sulfonic acid (ABTS) radical cation decolorization assay, and measurement of total polyphenolic content. To evaluate neuroprotective effect of BSGE in vitro, We performed thiazolyl blue tetrazolium bromide (MTT) assay, reactive oxygen species (ROS) creation in SH-SY5Y. Tyrosine hydroxylase (TH) immunocytochemistry, nitric oxide (NO) assay, and TNF-α assay in primary rat mesencephalic dopaminergic neurons. Results: The DPPH free radical and the ABTS radical cation inhibition activities were increased at a dose dependent manner. Total polyphenolic content was 0.83%. In SH-SY5Y culture, BSGE significantly increased the decreased cell viability by 6-OHDA at the concentrations of 10㎍/㎖ in pre-treatment group, 0.1-200㎍/㎖ in post-treatment group. The production of ROS induced by 6-OHDA was significantly inhibited in BSGE treated group. In mesencephalic dopaminergic cell culture, the BSGE group reduced the dopaminergic cell loss against 6-OHDA toxicity and the production of No and TNF-α at the concentration of 5㎍/㎖. Conclusion: These results shows that BSGE has antioxidant and neuroprotective effects in the dopaminergic cells through decreasing the production of ROS, NO and TNF-α which can cause many neurodegenerative changes in brain cell. We suggest that BSGE could be useful for the treatment of postmenopausal depression related with the decrease of dopamine.
참고문헌 (35)
- "2006년 생명표. 디지털 간행물 통계로 보는 여성의 삶. 2008"[URL]
- 박영주, "한국 여성의 폐경 연령, 갱년기 증상 관련 요인", 여성건강간호학회지, 7(4), pp.473~485 (2001)
- Avis NE, "Colvin A. A Universal menopausal syndrome?", Am J Med, 18(12), pp.37~46 (2005)
- Soares CN, "Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri-and postmenopausal women:impact on depression, vasomotor symptoms, sleep, and quality of life", Menopause, 13(5), pp.780~786 (2006)
- Joffe H, "Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine", J Clin Psychiatry, 68(6), pp.943~950 (2007)
- Dennerstein L, "The unique challenges of managing depression in mid-life women", World psychiatry, 7(3), pp.137~142 (2008)
- McIntyre RS, "Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship", CMAJ, 172(1), pp.57~59 (2005)
- Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Intiative randomizwd controlled trial", JAMA, 288(3), pp.321~333 (2002)
- 方譩姸, "스트레스와 갱년기 장애에 관한 문헌적 고찰", 동의신경정신과학회지, 3(2), pp.143~159 (1992)
- 김종우, "한의학에서 본 홧병의 해석", 동의신경정신과학회지, 5(1), pp.9~15 (1994)
- Wise DD, "Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The importance of Pregnancy, Vasomotor Symptom, and Other Estrogen-Related Events in Psychopharmaology", CNS Spectr, 13(8), pp.647~655 (2008)
- 劉景源, "太平惠民和劑局方", pp.1114~ (1985), 人民衛生出版社
- 여대원, "分心氣飮의 항암 작용 및 면역 기능에 관한 연구", 대한한방내과학회지, 24(2), pp.315~328 (2003)
- 전연이, "分心氣飮이 고혈압 백서와 인간 유래 혈관내피세포주(ECV304)에 미치는 영향에 대한 연구", 대한한방내과학회지, 26(1), pp.182~198 (2005)
- 이승기, "分心氣飮의 우울증 모델 흰쥐에 대한 실험적 연구", 대한한의학회지, 22(3), pp.129~140 (2001)
- 김지욱, "分心氣飮의 항스트레스 효과에 관한 실험적 연구", 대한한의학회지, 10(1), pp.42~52 (1989)
- 지선영, "分心氣飮 투여에 따른 Stress 관련 Hormone의 함량 변화에 관한 실험적 고찰", 동의신경정신과학회지, 3(2), pp.49~63 (1992)
- 허용석, "分心氣飮加味方이 수면 장애와 정서성에 미치는 영향", 동의신경정신과학회지, 11(2), pp.43~52 (2000)
- 김경욱, "分心氣飮加味方이 흰쥐의 수면 장애와 불안에 미치는 영향", 동의신경정신과학회지, 11(2), pp.53~62 (2000)
- 경희대학교한의과대학, "慶熙韓方處方集", pp.84~ (1997), 경희대학교 한의과대학 부속한방병원
- Markou A, "Estrogens and brain function", Hormones, 4(1), pp.9~17 (2005)
- Sawada H S, "Estradiol Protects Mesencephalic Dopaminergic Neurons From Oxidative Stress-Induced neuronal Death", J Neurosci Res, 54, pp.707~719 (1998)
- Chinta SJ, "Dopaminergic neurons", IJBCB, 37, pp.942~946 (2005)
- Zangen A, "Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens", Psychopharmacology, 155, pp.434~439 (2001)
- Lemke MR, "Depression and Parkinson's disease", J Neurol, 9(6), pp.24~27 (2004)
- Fahn S, "Neurodegeneration and neuroprotection in Parkinson Disease", NeuroRx, 1(1), pp.139~154 (2004)
- 許浚, "東醫寶鑑", pp.79~ (2005), 東醫寶鑑出版社
- 吉益東洞, "藥徵", pp.216~217 (2006), 청총
- Dauer W, "Parkinson's disease: mechanisms and models", Neuron, 39(6), pp.889~909 (2003)
- Singh S, "Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat", Indian J Med Res, 124(4), pp.419~426 (2006)
- Berridge MV, "Characterization of the cellular reduction of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction", Arch Biochem Biophys, 303(2), pp.474~482 (1993)
- Agarwal A, "Sharma RK Role of oxidative stress in female reproduction", Reprod Biol Endocrinol, 3(28), pp.1~21 (2005)
- Baker H, "Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: Relationship to size and neuronal density of the striatum", Proc Natl Acad Sci U S A, 77(7), pp.4369~4373 (1980)
- Wilms H, "Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications", Curr Pharm Des, 13, pp.1925~1928 (2007)
- Dehmer T, "Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo", J Neurochem, 74(5), pp.2213~2216 (2000)